R&D News | pharmaphorum

News

Illustration of a nerve cell on a colored background with light effects

Neurocrine slumps as Tourette's drug fails clinical trial

Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark.

News

Axovant axes neuroscience drug, focuses on gene therapies

Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin

News

Shinichi Tamura re-takes CEO role at Sosei

Sosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO as of next year.

News

Eisai, Takeda and GARDP hunt for new antibiotics

The not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for new antibiotics.

News

FDA clears Pear/Sandoz app for opioid use disorder

A second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more successful response to therapy has been given a green light by the FDA.

News

Boehringer follows Sanofi with job cuts in France

Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week.

Neurocrine slumps as Tourette's drug fails clinical trial

Axovant axes neuroscience drug, focuses on gene therapies

Shinichi Tamura re-takes CEO role at Sosei

Eisai, Takeda and GARDP hunt for new antibiotics

FDA clears Pear/Sandoz app for opioid use disorder

Boehringer follows Sanofi with job cuts in France

Google Cloud launches Gemini for Healthcare

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks